MODERN PECULIARITIES OF MYOCARDIAL CYTOPROTECTION IN THERAPY OF ISHEMIC HEART DISEASE PATIENTS

Abstract

Results of meta-analysis of more than 20 clinical studies of use of various dosages and schemes of indication of trimetazidine to stable ischemic heart disease patients allowed considering the daily dosage of trimetazidine 70 mg as a standard therapeutic dosage. With the help of the mathematical odeling it was shown that administration of Deprenorm®MV 70 mg once per day reduces the frequency of blood plasma concentration to 1 tpd instead of 2 tpd (every 12 hours) as compared to the reference drug. From the pharmacological point of view one time administration of Deprenorm ®MV 70 mg containing the standard daily dosage of trimetazidine has a more pronounced clinical effect as compared to administration of trimetazidine 35 mg 2 tpd and allows achieving higher compliance in ID patients.

Keywords

• ischemic heart disease
• chronic cardiac insufficiency
• angina pectoris
• preconditioning
• cyroprotection
• trimedazidine
• original drug
• generic
• drug therapy